Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis
Authors:
Open Access
Abstract
Objectives To investigate the differences of clinical features, cerebrospinal fluid (CSF), MRI findings and response to steroid therapies between patients with optic neuritis (ON) who have myelin oligodendrocyte glycoprotein (MOG) antibodies and those who have seronegative ON. Setting We recruited participants in the department of neurology and ophthalmology in our hospital in Japan. Methods We retrospectively evaluated the clinical features and response to steroid therapies of patients with ON. Sera from patients were tested for antibodies to MOG and aquaporin-4 (AQP4) with a cell-based assay. Participants Between April 2009 and March 2014, we enrolled serial 57 patients with ON (27 males, 30 females; age range 16–84 years) who ophthalmologists had diagnosed as having or suspected to have ON with acute visual impairment and declined critical flicker frequency, abnormal findings of brain MRI, optical coherence tomography and fluorescein fundus angiography at their onset or recurrence. We excluded those patients who fulfilled the diagnostic criteria of neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD), MS McDonald's criteria, and so on. Finally we defined 29 patients with idiopathic ON (14 males, 15 females, age range 16–84 years). Results 27.6% (8/29) were positive for MOG antibodies and 3.4% (1/29) were positive for AQP4. Among the eight patients with MOG antibodies, five had optic pain (p=0.001) and three had prodromal infection (p=0.179). Three of the eight MOG-positive patients showed significantly high CSF levels of myelin basic protein (p=0.021) and none were positive for oligoclonal band in CSF. On MRIs, seven MOG-positive patients showed high signal intensity on optic nerve, three had a cerebral lesion and one had a spinal cord lesion. Seven of the eight MOG-positive patients had a good response to steroid therapy. Conclusions Although not proving primary pathogenicity of anti-MOG antibodies, the present results indicate that the measurement of MOG antibodies is useful in diagnosing and treating ON.Keywords
This publication has 14 references indexed in Scilit:
- Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous systemJournal of Neuroimmunology, 2014
- Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patientsMultiple Sclerosis Journal, 2012
- Anti–Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Patients With Optic NeuritisArchives of Neurology, 2012
- Relationship Between NMO-Antibody and Anti–MOG Antibody in Optic NeuritisJournal of Neuro-Ophthalmology, 2012
- Natural History of the Visual Impairment of Relapsing Neuromyelitis OpticaOphthalmology, 2007
- Revised diagnostic criteria for neuromyelitis opticaNeurology, 2006
- Multiple Sclerosis — The Plaque and Its PathogenesisNew England Journal of Medicine, 2006
- Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.Journal of Clinical Investigation, 1993
- Differential Ultrastructural Localization of Myelin Basic Protein, Myelin/Oligodendroglial Glycoprotein, and 2′,3′‐Cyclic Nucleotide 3′‐Phosphodiesterase in the CNS of Adult RatsJournal of Neurochemistry, 1989
- A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease.The Journal of Immunology, 1987